Fonds de solidarité FTQ's Gravel, Orbimed's Zakrzewski join Thrasos board
Thrasos Therapeutics, a biotherapeutics company focused on delivering new treatments for kidney disease, has appointed Gaétan Gravel and Joe Zakrzewski to its board of directors. Gravel is the life sciences portfolio director at the Fonds de solidarité des travailleurs du Québec FTQ. Zakrzewski was between 2010 and 2011 a venture partner at U.S. venture capital firm Orbimed Advisors. In 2012, Montréal's Thrasos raised $35 million from SR One, GSK Canada Life Sciences Innovation Fund, SW Co, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.
13 August 2014•4 mins read
